Tenax Therapeutics granted US patent covering IV levosimendan for PH-HFpEF until 2040

TENAX THERAPEUTICS, INC.

USPTO Notice of Allowance for patent covering IV levosimendan in PH-HFpEF; patent expected to last until 2040.
No FDA-approved treatments exist for PH-HFpEF, which affects over 1.5 million patients in the US.
HELP Study showed levosimendan improved 6-minute walk distance by 29 meters (p=0.03); FDA accepted endpoint for Phase 3.
Patent builds on existing U.S. Patent No. 11,213,524 for subcutaneous levosimendan issued Jan 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.